Aurinia Pharmaceuticals Inc (AUPH) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Aurinia Pharmaceuticals Inc   (NASDAQ: AUPH)


Aurinia Pharmaceuticals Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Aurinia Pharmaceuticals Inc's ROI in the third quarter of 2026?
Aurinia Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 49.14 % in its third quarter of 2026, this is above AUPH's average return on investment of -10.6%.
Aurinia Pharmaceuticals Inc invested over the 12 months ending in its third quarter of 2026 $639 million

ROI decreased relative to the period ending Jun 30 2026, due to the decline in net income.

Within the Healthcare sector 27 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 83, from total ROI ranking in the second quarter of 2026 at 92.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 61.81 % 43.46 % 25.22 % 15.47 % 1.48 %
Y / Y Net Income Change TTM 303.75 % 418.03 % 662.24 % 1720.15 % 442.42 %
Investment (TTM) in Millions 698 663 580 616 403
Return On Investment (TTM) 49.14 % 55.53 % 60.4 % 64.08 % 19.7 %
AUPH's Overall Ranking # 83 # 92 # 76 # 287 #
Seq. Investment Change TTM 13.06 % 14.56 % 10.15 % 13.41 % 0.24 %
Seq. Net Income Change TTM 0.05 % 5.33 % 3.83 % 268.98 % 28.37 %
Net Income (TTM) in Millions 314 314 298 287 78

AUPH Company Profile >> Back to AUPH Roi Comparisons >> See Annual AUPH Return On Investment



Return On Investment AUPH's Ranking
Within: No.
Industry # 15
Sector # 28
Overall # 83

Return On Investment Statistics
High Average Low
56.37 %
-10.6 %
-45.8 %
(Dec 31 2025)   (Dec 31 2021)







Financial Statements
Aurinia Pharmaceuticals Inc's III. Quarter Investments $ 698 Millions AUPH's Balance sheet
Aurinia Pharmaceuticals Inc's III. Quarter Income $ 32 Millions Quarterly AUPH's Income Statement
AUPH's Income by Division See AUPH's Income by Division


AUPH Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 690 404 409 427 505
Y / Y Investment Growth 70.51 % -1.25 % -4 % -15.52 % 16.6 %
Net Income in Millions 287 6 -78 -108 -181
Y / Y Net Income Growth 4893.08 % - - - -
Annual Return On Investment 41.65 % 1.42 % -19.05 % -25.36 % -35.84 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 41.65 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
AUPH's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for AUPH's Competitors
Subscribers only: Roi for Aurinia Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for AUPH's Customers

Other Ratios
AUPH's Roa AUPH's Inventory Turnover Ratio AUPH's Growth Rates AUPH's Dividend Statistics
AUPH's Profitability Ratios AUPH's Asset Turnover Ratio AUPH's Dividend Growth
AUPH's Roe AUPH's Valuation Ratios AUPH's Financial Strength Ratios AUPH's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Arbutus Biopharma Corp  120.80 %
Indivior Pharmaceuticals Inc   108.22 %
Lensar Inc   94.32 %
Exelixis Inc   75.01 %
Ironwood Pharmaceuticals inc   68.68 %
Rigel Pharmaceuticals Inc  68.50 %
Alnylam Pharmaceuticals Inc   63.14 %
Idexx Laboratories Inc  52.51 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Protalix Biotherapeutics inc   26.06 %
Standard Biotools Inc   23.91 %
Electromed Inc   23.41 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %

Date modified: 2026-10-31T17:30:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.